Alpha 1-antitrypsin deficiency screening: Difference between revisions
Mazia Fatima (talk | contribs) No edit summary |
|||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Alpha 1-antitrypsin deficiency}} | {{Alpha 1-antitrypsin deficiency}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{Mazia}} | ||
{{ | |||
==Overview== | ==Overview== | ||
According to the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), | According to the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), all [[Chronic obstructive pulmonary disease|COPD]] [[patients]] should be [[Screening|screened]] for AATD at least once in their lifetime. All [[patients]] with unexplained [[Liver diseases|liver disease]] with or without [[Respiratory|respiratory symptoms]] should be evaluated for AATD. | ||
==Screening== | ==Screening== | ||
*According to the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), | [[Screening]] for alpha 1-antitrypsin deficiency includes:<ref name="pmid29225784">{{cite journal |vauthors=Hersh CP |title=Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicine |journal=F1000Res |volume=6 |issue= |pages=2049 |year=2017 |pmid=29225784 |pmc=5710307 |doi=10.12688/f1000research.12399.1 |url=}}</ref><ref name="pmid28929906">{{cite journal |vauthors=Lascano JE, Campos MA |title=The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency |journal=Postgrad Med |volume=129 |issue=8 |pages=889–895 |year=2017 |pmid=28929906 |doi=10.1080/00325481.2017.1381539 |url=}}</ref> | ||
* | *According to the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), all [[Chronic obstructive pulmonary disease|COPD]] [[patients]] should be [[Screening (medicine)|screened]] for AATD at least once in their lifetime. | ||
*All patients with unexplained [[Liver diseases|liver disease]] with or without [[Respiratory|respiratory symptoms]] should be evaluated for AATD. | |||
*Adults with [[necrotizing]] [[panniculitis]] should be screened. | |||
==References== | ==References== | ||
Latest revision as of 17:46, 22 January 2018
|
Alpha 1-antitrypsin deficiency Microchapters |
|
Differentiating Alpha 1-antitrypsin deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Alpha 1-antitrypsin deficiency screening On the Web |
|
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency screening |
|
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency |
|
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]
Overview
According to the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), all COPD patients should be screened for AATD at least once in their lifetime. All patients with unexplained liver disease with or without respiratory symptoms should be evaluated for AATD.
Screening
Screening for alpha 1-antitrypsin deficiency includes:[1][2]
- According to the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), all COPD patients should be screened for AATD at least once in their lifetime.
- All patients with unexplained liver disease with or without respiratory symptoms should be evaluated for AATD.
- Adults with necrotizing panniculitis should be screened.
References
- ↑ Hersh CP (2017). "Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicine". F1000Res. 6: 2049. doi:10.12688/f1000research.12399.1. PMC 5710307. PMID 29225784.
- ↑ Lascano JE, Campos MA (2017). "The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency". Postgrad Med. 129 (8): 889–895. doi:10.1080/00325481.2017.1381539. PMID 28929906.